Author

H. M. Xie

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

A. Lenard· 2 shared K. M. Bernt· 2 shared S. S. Riedel· 2 shared B. Manning· 1 shared C. Falkenstein· 1 shared C. Libbrecht· 1 shared F. Alikarami· 1 shared G. McGeehan· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Lenard

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivMar 16, 2023

Clonal evolution mediates Menin-inhibitor resistance in KMT2A-rearranged leukemias.

L. Mahdavi, H. Goodrow, F. Alikarami…·K. M. Bernt

This study shows that Menin-inhibitor resistance in KMT2A-rearranged leukemias arises through clonal evolution, with resistance developing without prior exposure to the inhibitor.

DOI 10.1016/j.exphem.2025.105268

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivOct 2, 2019

Epigenetic regulation of protein translation in KMT2A-rearranged AML

A. Lenard, H. M. Xie, S. S. Riedel…·K. M. Bernt

This paper evaluates combinations of DOT1L and EZH2 inhibitors in KMT2A-rearranged AML, finding synergistic effects with a protein translation inhibitor but not with EZH2 inhibition.

DOI 10.1016/j.exphem.2020.04.007

humanmouse

𝕏 PostBluesky